Abstract
The use of dendritic cells (DCs) in the cancer immunotherapy has shown to be promising and Food and Drug Administration (FDA) approved the first DCs vaccine for metastatic prostate cancer patients in 2010. DCs are able to trigger antitumor adaptive immunity through the adequate processing and presentation of tumor antigen associated with major histocompatibility complex (MHC) molecules fo…